SCHEMBL1101136

SCHEMBL1101136

NNC1CCCc2ccccc21

nearest known ligand 0.68

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.55
HTT P42858 1/20 0.55
ALDH1A1 P00352 2/20 0.54
IDO1 P14902 2/20 0.53
KMT2A Q03164 2/20 0.53
MEN1 O00255 1/20 0.53
EPHX1 P07099 1/20 0.53
PDPK1 O15530 1/20 0.52
ADRA2A P08913 2/20 0.51
ADRA2B P18089 2/20 0.51
ADRA2C P18825 2/20 0.51
ADRA1A P35348 2/20 0.51
TAS1R3 Q7RTX0 2/20 0.50
TAS1R1 Q7RTX1 2/20 0.50
TAS1R2 Q8TE23 2/20 0.50
HDAC6 Q9UBN7 1/20 0.49
KCNN3 Q9UGI6 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18539295 1.00 LMNA (0.55) LMNAHTTALDH1A1IDO1KMT2A
SCHEMBL18539244 1.00 LMNA (0.55) LMNAHTTALDH1A1IDO1KMT2A
SCHEMBL18539280 0.88 PDPK1 (0.66) IDO1PDPK1ADRA2BADRA2CADRA1A
SCHEMBL31388654 0.88 PDPK1 (0.66) IDO1PDPK1ADRA2BADRA2CADRA1A
SCHEMBL1691714 0.88 PDPK1 (0.66) IDO1PDPK1ADRA2BADRA2CADRA1A
Hydrochloric Acid SCHEMBL7141983 0.86 PDPK1 (0.63) IDO1PDPK1ADRA2BADRA2CADRA1A
SCHEMBL2115700 0.84 HTT (0.63) LMNAHTTALDH1A1KMT2AMEN1
SCHEMBL61094 0.81 PDPK1 (0.79) LMNAHTTALDH1A1KMT2AMEN1
SCHEMBL6344102 0.81 HTT (0.59) LMNAHTTALDH1A1KMT2AMEN1
SCHEMBL61380 0.81 PDPK1 (0.79) LMNAHTTALDH1A1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8952031-B2 Amino- and amido-aminotetralin derivatives and related compounds as mu opioid receptor antagonists THERAVANCE BIOPHARMA R&D IP, LLC (US) 2015-02-10 US disclosed
US-8952031-B2 Amino- and amido-aminotetralin derivatives and related compounds as mu opioid receptor antagonists THERAVANCE BIOPHARMA R&D IP, LLC (US) 2015-02-10 US disclosed
US-8952031-B2 Amino- and amido-aminotetralin derivatives and related compounds as mu opioid receptor antagonists THERAVANCE BIOPHARMA R&D IP, LLC (US) 2015-02-10 US disclosed
EP-2280933-B1 2 -AMINOTETRALIN DERIVATIVES AS MU OPIOID RECEPTOR ANTAGONISTS THERAVANCE INC (US) 2013-07-24 EP disclosed
US-20120165360-A1 AMINO- AND AMIDO-AMINOTETRALIN DERIVATIVES AND RELATED COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS THERAVANCE, INC. (US) 2012-06-28 US disclosed
US-20120165360-A1 AMINO- AND AMIDO-AMINOTETRALIN DERIVATIVES AND RELATED COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS THERAVANCE, INC. (US) 2012-06-28 US disclosed
US-8153686-B2 Amino- and amido-aminotetralin derivatives and related compounds as mu opioid receptor antagonists THERAVANCE, INC. (US) 2012-04-10 US disclosed
US-8153686-B2 Amino- and amido-aminotetralin derivatives and related compounds as mu opioid receptor antagonists THERAVANCE, INC. (US) 2012-04-10 US disclosed
US-8153686-B2 Amino- and amido-aminotetralin derivatives and related compounds as mu opioid receptor antagonists THERAVANCE, INC. (US) 2012-04-10 US disclosed
EP-2280933-A1 2 -AMINOTETRALIN DERIVATIVES AS MU OPIOID RECEPTOR ANTAGONISTS Theravance, Inc. (US) 2011-02-09 EP disclosed
EP-2280933-A1 2 -AMINOTETRALIN DERIVATIVES AS MU OPIOID RECEPTOR ANTAGONISTS Theravance, Inc. (US) 2011-02-09 EP disclosed
WO-2009124022-A1 2 -AMINOTETRALIN DERIVATIVES AS MU OPIOID RECEPTOR ANTAGONISTS THERAVANCE, INC. (US) 2009-10-08 WO disclosed
WO-2009124022-A1 2 -AMINOTETRALIN DERIVATIVES AS MU OPIOID RECEPTOR ANTAGONISTS THERAVANCE, INC. (US) 2009-10-08 WO disclosed
US-20090247627-A1 AMINO- AND AMIDO-AMINOTETRALIN DERIVATIVES AND RELATED COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS THERAVANCE BIOPHARMA R&D IP, LLC 2009-10-01 US disclosed
US-20090247627-A1 AMINO- AND AMIDO-AMINOTETRALIN DERIVATIVES AND RELATED COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS THERAVANCE BIOPHARMA R&D IP, LLC 2009-10-01 US disclosed
US-6525222-B2 By reacting aldehydes or ketones at high temperature and pressure with ammonia, amines and hydrogen in the presence of a catalyst mixed oxide of zirconium, copper, nickel, cobalt, and optionally molybdenum, aluminum and manganese BASF AKTIENGESELLSCHAFT (DE) 2003-02-25 US disclosed
US-20010003136-A1 Process for preparing amines BASF AKTIENGESELLSCHAFT (DE) 2001-06-07 US disclosed
EP-0073960-A1 2-Arylhydrazino-2-imidazolines, their acyl derivatives, process for their preparation and their use in the control of endoparasites and ectoparasites BAYER AG (DE) 1983-03-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010003136-A1 Process for preparing amines AOC2, AOC3, SOD1 LMNA 3670/4885HTT 3635/4885ALDH1A1 1280/4885
US-20120165360-A1 AMINO- AND AMIDO-AMINOTETRALIN DERIVATIVES AND RELATED COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS OPRL1, OPRM1, OPRD1 LMNA 4668/4885HTT 1009/4885ALDH1A1 1590/4885
US-20090247627-A1 AMINO- AND AMIDO-AMINOTETRALIN DERIVATIVES AND RELATED COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS OPRL1, OPRM1, OPRD1 LMNA 4668/4885HTT 1009/4885ALDH1A1 1590/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.